Umberto Foresta

发表

In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma

M. Cannataro, P. Guzzi, P. Tassone, 2013, Oncotarget.

Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence

M. Negrini, N. Munshi, P. Tassone, 2012, Clinical Cancer Research.

In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma

M. Cannataro, R. Franco, P. Guzzi, 2014, PloS one.

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.

K. Anderson, N. Munshi, S. Molica, 2012, Blood.

miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1

N. Munshi, P. Tassone, P. Tagliaferri, 2012, Cell Death and Disease.

A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells

N. Munshi, P. Tassone, T. Calimeri, 2011, Leukemia.

Selective G-Protein Estrogen Receptor (GPER) Activation Triggers Anti-Multiple Myeloma Activity and Synergizes with MiR-29b-Inducing Drugs

P. Tassone, T. Calimeri, P. Tagliaferri, 2014 .

Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth

N. Munshi, P. Tassone, P. Tagliaferri, 2013, Clinical Cancer Research.